Patented Organic Medical Food (Plant Based Oil)  to compensate/manage an impaired Δ-6 desaturase / inflammation as evaluated by your physician.*

Here's What You're Getting Access To:

  • A 15-minute video explaining the 'Delta-6 Desaturase Pathway' that is responsible for regulating (systemic) inflammation.
  • ​A library of evidence based research and patient case studies revealing how an impaired 'D-6 Enzyme' induces systemic inflammation and inhibits Cardiovascular Function, Cellular Oxygenation, Wound Healing, and more.
  • ​How the medical food Brivanta™ helps manage inflammation in those who are suffering from chronic wounds, ulcers, neurodegeneration, cardiovascular disease, and much more. (And the metabolic pathway in-which it works)
About Us:
For the last 25+ years, we have taken Nobel Prize winning research in  Physiology and Bio-Chemistry, and used these great studies to create a simple solution for todays most debilitating and prevalent illnesses.

The health supplement precursor of Brivanta™ was granted a United States Patent in 2010 for; "A medicament for the treatment of cancer"

After achieving great success, we realized that we needed a "Clinical Strength Formulation" that physicians can provide for the their patients who are suffering from **diseases and disorders from an Impaired Δ-6 Desaturase Pathway causing chronic inflammation.

Thus, the medical food Brivanta™ was created and was also granted United States & Canadian Patents for "Medicament for treatment of cancer, cardiovascular diseases and inflammation"

- David Sim, M.D. (Interventional Cardiologist)

"This corresponds to a seventy-three (73%) effectiveness rating. The average improvement in arterial flexibility was 9 years improvement meaning the average subject utilizing the formulation (Brivanta precursor) had a cardiovascular system with the arterial flexibility of a subject representative of nearly a decade younger."

- Kelvin Lindgren, M.D. (Otolaryngologist/ENT)

"Thanks to you and your discovery (Brivanta Precursor), he (the patient) is back to playing golf, walking the course. All medical professionals need to know about the science behind this product."

- Robert L. Kagan (Nuclear Medicine Specialist)

"I previously wrote you about the remarkable cause / effect relationship in reversing plaque volume in a (smoking) patient taking conventional treatment (i.e. statins, aspirin, Co-Q10, etc.). In reading over [the patient’s] scans I have never seen such a remarkable result. When he [the patient] stopped the product (Brivanta Precursor), the plaque came back!"

*What Is A Medical Food?

"The term medical food, as defined in section 5(b) of the Orphan Drug Act (21 U.S.C. 360ee (b) (3)) is "a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation."

Manufacturers of medical foods must comply with all applicable FDA requirements for foods, including the following regulations:
• Current good manufacturing practice (21 CFR part 110);
• Registration of food facilities (21 CFR part 1 subpart H);
• Thermally processed low-acid foods packaged in hermetically sealed containers (21 CFR part 113);
• Acidified foods (21 CFR part 114); and
• Emergency permit control (21 CFR part 108).

Medical foods are not drugs and, therefore, are not subject to any regulatory requirements that specifically apply to drugs. Medical foods are also not health supplements which can not make medical claims.

**What Diseases, Disorders & Impairments Does Brivanta™ manage?

• Diabetes (Type 1 & Type 2) including Neuropathy
• Lipid-Enveloped Viruses (including COVID series)
• Alzheimer’s
• Dermatological Conditions
• Cardiovascular Disease
• Inflammatory Bowel Disease
• Chronic Fatigue (including post viral syndromes)
• Fatty Liver Disease Including NAFLD
• Cancer
• Arthritis
• Multiple Sclerosis 

Respiratory Diseases With Chronic Inflammation
• Mesothelioma
• Idiopathic Pulmonary Fibrosis (IPF)
• Chronic Obstructive Pulmonary Disease (COPD)

Brivanta™

www.Brivanta.com - Copyright 2025 - Terms - Privacy

Oxygen4Life, Inc. is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Title III of the JOBS Act and Regulation CF. A copy of the Form C that forms a part of the Offering Statement may be obtained from: Form C

Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Any past performance described is not indicative of future results. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.


DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 4000 Eagle Point Corporate Drive, Suite 950, Birmingham, AL 35242, is the Intermediary for this offering and is not an affiliate of or connected with the Issuer. Please check our background on FINRA's BrokerCheck

DealMaker Securities LLC does not make investment recommendations.

DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer.

DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor’s documentation for this investment.

DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing.

DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself.

 Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.

This website contains forward-looking statements. These statements may include the words “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate”, “project”, “will”, “may”, “targeting” and similar expressions as well as statements other than statements of historical facts including, without limitation, those regarding the financial position, business strategy, plans, targets and objectives of the management of Oxygen4Life, Inc. for future operations (including development plans and objectives). Such forward-looking statements involve known and unknown risks, uncertainties and other important factors which may affect the Company's ability to implement and achieve the economic and monetary policies, budgetary plans, fiscal guidelines and other development benchmarks set out in such forward-looking statements and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future policies and plans and the environment in which the Company will operate in the future. Furthermore, certain forward-looking statements are based on assumptions or future events which may not prove to be accurate, and no reliance whatsoever should be placed on any forward-looking statements in this presentation. The forward-looking statements in this website speak only as of the date of the Company's initial Form C, and the Company expressly disclaims to the fullest extent permitted by law any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.